Literature DB >> 22030092

Comorbidities and outcomes: advancing the field comes at a price.

Mohamed L Sorror1.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 22030092      PMCID： PMC3397778          DOI： 10.1016/j.bbmt.2011.10.026

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  8 in total

Review 1.  Measuring comorbidity in older cancer patients.

Authors:  M Extermann
Journal:  Eur J Cancer       Date:  2000-03       Impact factor: 9.162

2.  Assignment of scores for the hematopoietic cell transplantation comorbidity index: integer vs exact weights.

Authors:  M L Sorror; B Storer; R Storb
Journal:  Bone Marrow Transplant       Date:  2010-05-31       Impact factor: 5.483

3.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Authors:  Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

4.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

5.  The hematopoietic cell transplantation-specific comorbidity index fails to predict outcomes in high-risk AML patients undergoing allogeneic transplantation--investigation of potential limitations of the index.

Authors:  Nicole Birninger; Martin Bornhäuser; Markus Schaich; Gerhard Ehninger; Johannes Schetelig
Journal:  Biol Blood Marrow Transplant       Date:  2011-06-25       Impact factor: 5.742

Review 6.  Comorbidities and hematopoietic cell transplantation outcomes.

Authors:  Mohamed L Sorror
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2010

7.  Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.

Authors:  Roland B Walter; Megan Othus; Gautam Borthakur; Farhad Ravandi; Jorge E Cortes; Sherry A Pierce; Frederick R Appelbaum; Hagop A Kantarjian; Elihu H Estey
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

8.  Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.

Authors:  Mohamed L Sorror; Brenda M Sandmaier; Barry E Storer; Georg N Franke; Ginna G Laport; Thomas R Chauncey; Edward Agura; Richard T Maziarz; Amelia Langston; Parameswaran Hari; Michael A Pulsipher; Wolfgang Bethge; Firoozeh Sahebi; Benedetto Bruno; Michael B Maris; Andrew Yeager; Finn Bo Petersen; Lars Vindeløv; Peter A McSweeney; Kai Hübel; Marco Mielcarek; George E Georges; Dietger Niederwieser; Karl G Blume; David G Maloney; Rainer Storb
Journal:  JAMA       Date:  2011-11-02       Impact factor: 56.272
  8 in total
  2 in total

1.  How I assess comorbidities before hematopoietic cell transplantation.

Authors:  Mohamed L Sorror
Journal:  Blood       Date:  2013-01-25       Impact factor: 22.113

2.  Comorbidity burden in patients with chronic GVHD.

Authors:  W A Wood; X Chai; D Weisdorf; P J Martin; C Cutler; Y Inamoto; D Wolff; S Z Pavletic; J Pidala; J M Palmer; M Arora; S Arai; M Jagasia; B Storer; S J Lee; S Mitchell
Journal:  Bone Marrow Transplant       Date:  2013-05-13       Impact factor: 5.483
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.